Kaw Yan Chua
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kaw Yan Chua has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
B. W. Lee
Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
5 shared publicationsN. Cheong
Department of Paediatrics, National University of Singapore, Singapore, Singapore
4 shared publicationsI-Chun Kuo
3 shared publicationsC. H. Huang
Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
2 shared publicationsChiung Hui Huang
Departments of Paediatrics
2 shared publicationsChiung-Hui Huang
2 shared publications
Latest Publications
- Open Access
- 26 August 2011
- Published by Springer Nature in BMC Microbiology
- Vol. 11 (1) , 193
Evaluation of stool microbiota signatures in two cohorts of Asian (Singapore and Indonesia) newborns at risk of atopy
Background: Studies have suggested that demographic and lifestyle factors could shape the composition of fecal microbiota in early life. This study evaluated infant stool microbiota signatures in two Asian populations, Singapore (n = 42) and Indonesia (n = 32) with contrasting socioeconomic development, and examined the putative influences of demographic factors on these human fecal associated bacterial signatures.Results: Longitudinal analysis showed associations of geographical origin withClostridium leptum, AtopobiumandBifidobacteriumgroups. Mode of delivery had the largest effect on stool microbiota signatures influencing the abundance of four bacterial groups. Significantly higher abundance of bacterial members belonging to theBacteroides-Prevotella, BifidobacteriumandAtopobiumgroups, but lower abundance ofLactobacilli-Enterococcigroup members, were observed in vaginal delivered compared to caesarean delivered infants. Demographic factors influencing the structure of infants stool microbiota during the first year of life included breastfeeding, age of weaning, sibship size and exposure to antibiotics.Conclusions: Differences in stool microbiota signatures were observed in relation to various demographic factors. These features may confound studies relating to the association of the structure of fecal microbiota and the predisposition to human modern disease.
- 26 August 2011
- Published by Springer Nature in BMC Microbiology
- Vol. 11 (1) , 193
Open AccessEvaluation of stool microbiota signatures in two cohorts of Asian (Singapore and Indonesia) newborns at risk of atopy
Background: Studies have suggested that demographic and lifestyle factors could shape the composition of fecal microbiota in early life. This study evaluated infant stool microbiota signatures in two Asian populations, Singapore (n = 42) and Indonesia (n = 32) with contrasting socioeconomic development, and examined the putative influences of demographic factors on these human fecal associated bacterial signatures.Results: Longitudinal analysis showed associations of geographical origin withClostridium leptum, AtopobiumandBifidobacteriumgroups. Mode of delivery had the largest effect on stool microbiota signatures influencing the abundance of four bacterial groups. Significantly higher abundance of bacterial members belonging to theBacteroides-Prevotella, BifidobacteriumandAtopobiumgroups, but lower abundance ofLactobacilli-Enterococcigroup members, were observed in vaginal delivered compared to caesarean delivered infants. Demographic factors influencing the structure of infants stool microbiota during the first year of life included breastfeeding, age of weaning, sibship size and exposure to antibiotics.Conclusions: Differences in stool microbiota signatures were observed in relation to various demographic factors. These features may confound studies relating to the association of the structure of fecal microbiota and the predisposition to human modern disease.
- Open Access
- 4 August 2009
- Published by Wiley in Immunology
- Vol. 128 (1pt2) , e881-e894
Coadministration of the fungal immunomodulatory protein FIP‐Fve and a tumour‐associated antigen enhanced antitumour immunity
Summary: Fve is a fungal protein isolated from the golden needle mushroom Flammulina velutipes and has previously been reported to trigger immunological responses in both mouse and human lymphocytes. In this study, we evaluated the potential application of Fve as an adjuvant for tumour immunotherapy and examined the underlying mechanism(s). When the human papillomavirus (HPV)‐16 E7 oncoprotein was used as a model antigen, mice coimmunized with HPV‐16 E7 and Fve showed enhanced production of HPV‐16 E7‐specific antibodies as well as expansion of HPV‐16 E7‐specific interferon (IFN)‐γ‐producing CD4+ and CD8+ T cells as compared with mice immunized with HPV‐16 E7 alone. Tumour protection assays showed that 60% of mice coimmunized with HPV‐16 E7 plus Fve, as compared with 20% of those immunized only with HPV‐16 E7, remained tumour‐free for up to 167 days after challenge with the tumour cells. Tumour therapeutic assays showed that HPV‐16 E7 plus Fve treatment significantly prolonged the survival of tumour‐bearing mice as compared with those treated only with HPV‐16 E7. In vivo cell depletion and adoptive T‐cell transfer assays showed that CD4+ and CD8+ T cells and IFN‐γ played critical roles in conferring the antitumour effects. Interestingly, Fve could stimulate the maturation of splenic dendritic cells in vivo and induce antigen‐specific CD8+ T‐cell immune responses. In summary, Fve has potent adjuvant properties that enhance T helper type 1 antigen‐specific humoral and cellular immune responses which confer strong antitumour effects. The use of Fve as an adjuvant could be an attractive alternative to the current vaccination strategy for cancer immunotherapy.
- 4 August 2009
- Published by Wiley in Immunology
- Vol. 128 (1pt2) , e881-e894
Open AccessCoadministration of the fungal immunomodulatory protein FIP‐Fve and a tumour‐associated antigen enhanced antitumour immunity
Summary: Fve is a fungal protein isolated from the golden needle mushroom Flammulina velutipes and has previously been reported to trigger immunological responses in both mouse and human lymphocytes. In this study, we evaluated the potential application of Fve as an adjuvant for tumour immunotherapy and examined the underlying mechanism(s). When the human papillomavirus (HPV)‐16 E7 oncoprotein was used as a model antigen, mice coimmunized with HPV‐16 E7 and Fve showed enhanced production of HPV‐16 E7‐specific antibodies as well as expansion of HPV‐16 E7‐specific interferon (IFN)‐γ‐producing CD4+ and CD8+ T cells as compared with mice immunized with HPV‐16 E7 alone. Tumour protection assays showed that 60% of mice coimmunized with HPV‐16 E7 plus Fve, as compared with 20% of those immunized only with HPV‐16 E7, remained tumour‐free for up to 167 days after challenge with the tumour cells. Tumour therapeutic assays showed that HPV‐16 E7 plus Fve treatment significantly prolonged the survival of tumour‐bearing mice as compared with those treated only with HPV‐16 E7. In vivo cell depletion and adoptive T‐cell transfer assays showed that CD4+ and CD8+ T cells and IFN‐γ played critical roles in conferring the antitumour effects. Interestingly, Fve could stimulate the maturation of splenic dendritic cells in vivo and induce antigen‐specific CD8+ T‐cell immune responses. In summary, Fve has potent adjuvant properties that enhance T helper type 1 antigen‐specific humoral and cellular immune responses which confer strong antitumour effects. The use of Fve as an adjuvant could be an attractive alternative to the current vaccination strategy for cancer immunotherapy.
- 1 February 2009
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 9 (1) , 50-54
DNA vaccines for the prevention and treatment of allergy
Antiallergy DNA vaccine is an attractive alternative for the prevention and treatment of allergic diseases. This review covers recent studies to enhance potency and safety of antiallergy DNA vaccines. Dendritic cell-targeted allergen gene vaccination using fascin gene promoter inhibited IgE production and allergic inflammation but not airway hyperresponsiveness. Targeting allergen expression at immature dendritic cells or induction of tolerogenic dendritic cells could induce antiallergic T regulatory cells. Vaccination with DNA-encoded Ag85B and AIMP1 as adjuvants could downregulate established Th2-mediated allergic responses. Forced ubiquitation or targeting allergens to lysosomal/endosomal compartments could avoid risk of allergen sensitization. Gene gun delivery of conventional antiallergy DNA vaccine is a risk factor. Replicase-based allergy DNA vaccines showed enhanced immunogenecity and safety as compared to conventional DNA vaccines. TANK-binding kinase-1 (TBK1) is a novel key molecule in DNA vaccine-induced immunogenicity. Dendritic cell-based approach has been actively explored to enhance immunogenicity of antiallergy DNA vaccines. Codelivery of hypoallergenic DNA vaccines with potent adjuvants via a desirable delivery mode will help to fulfill the requirements for clinical application of antiallergy DNA vaccines. Activation of TBK1 signaling pathway could be a novel strategy to enhance immunogenicity of DNA vaccines.
- 1 February 2009
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 9 (1) , 50-54
DNA vaccines for the prevention and treatment of allergy
Antiallergy DNA vaccine is an attractive alternative for the prevention and treatment of allergic diseases. This review covers recent studies to enhance potency and safety of antiallergy DNA vaccines. Dendritic cell-targeted allergen gene vaccination using fascin gene promoter inhibited IgE production and allergic inflammation but not airway hyperresponsiveness. Targeting allergen expression at immature dendritic cells or induction of tolerogenic dendritic cells could induce antiallergic T regulatory cells. Vaccination with DNA-encoded Ag85B and AIMP1 as adjuvants could downregulate established Th2-mediated allergic responses. Forced ubiquitation or targeting allergens to lysosomal/endosomal compartments could avoid risk of allergen sensitization. Gene gun delivery of conventional antiallergy DNA vaccine is a risk factor. Replicase-based allergy DNA vaccines showed enhanced immunogenecity and safety as compared to conventional DNA vaccines. TANK-binding kinase-1 (TBK1) is a novel key molecule in DNA vaccine-induced immunogenicity. Dendritic cell-based approach has been actively explored to enhance immunogenicity of antiallergy DNA vaccines. Codelivery of hypoallergenic DNA vaccines with potent adjuvants via a desirable delivery mode will help to fulfill the requirements for clinical application of antiallergy DNA vaccines. Activation of TBK1 signaling pathway could be a novel strategy to enhance immunogenicity of DNA vaccines.
- Open Access
- 5 September 2008
- Published by Wiley in Immunology
- Vol. 125 (2) , 218-228
The modulatory effects of lipopolysaccharide‐stimulated B cells on differential T‐cell polarization
Summary: Lipopolysaccharide (LPS) is a major component of environmental microbial products. Studies have defined the LPS dose as a critical determining factor in driving differential T‐cell polarization but the direct effects of LPS on individual antigen‐presenting cells is unknown. Here, we investigated the effects of LPS doses on naive B cells and the subsequent modulatory effects of these LPS‐activated B cells on T‐cell polarization. The LPS was able to induce a proliferative response starting at a dose of 100 ng/ml and was capable of enhancing antigen internalization at a dose of 1 μg/ml in naive B cells. Following LPS stimulation, up‐regulation of the surface markers CD40, CD86, I‐Ad, immunoglobulin M, CD54 and interleukin‐10 production, accompanied by down‐regulation of CD5 and CD184 (CXCR4) were observed in a LPS dose‐dependent manner. Low doses (< 10 ng/ml) of LPS‐activated B cells drove T helper type 2 polarization whereas high doses (> 0·1 μg/ml) of LPS‐activated B cells resulted in T regulatory type 1 cell polarization. In conclusion, LPS‐activated B cells acquire differential modulatory effects on T‐cell polarization. Such modulatory effects of B cells are dependent on the stimulation with LPS in a dose‐dependent manner. These observations may provide one of the mechanistic explanations for the influence of environmental microbes on the development of allergic diseases.
- 5 September 2008
- Published by Wiley in Immunology
- Vol. 125 (2) , 218-228
Open AccessThe modulatory effects of lipopolysaccharide‐stimulated B cells on differential T‐cell polarization
Summary: Lipopolysaccharide (LPS) is a major component of environmental microbial products. Studies have defined the LPS dose as a critical determining factor in driving differential T‐cell polarization but the direct effects of LPS on individual antigen‐presenting cells is unknown. Here, we investigated the effects of LPS doses on naive B cells and the subsequent modulatory effects of these LPS‐activated B cells on T‐cell polarization. The LPS was able to induce a proliferative response starting at a dose of 100 ng/ml and was capable of enhancing antigen internalization at a dose of 1 μg/ml in naive B cells. Following LPS stimulation, up‐regulation of the surface markers CD40, CD86, I‐Ad, immunoglobulin M, CD54 and interleukin‐10 production, accompanied by down‐regulation of CD5 and CD184 (CXCR4) were observed in a LPS dose‐dependent manner. Low doses (< 10 ng/ml) of LPS‐activated B cells drove T helper type 2 polarization whereas high doses (> 0·1 μg/ml) of LPS‐activated B cells resulted in T regulatory type 1 cell polarization. In conclusion, LPS‐activated B cells acquire differential modulatory effects on T‐cell polarization. Such modulatory effects of B cells are dependent on the stimulation with LPS in a dose‐dependent manner. These observations may provide one of the mechanistic explanations for the influence of environmental microbes on the development of allergic diseases.
- 12 May 2006
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 33 (5-6) , 546-550
DNA VACCINES AND ALLERGIC DISEASES
1. Allergic diseases are characterized by inappropriate immune responses to common environmental antigens. The prevalence of these diseases has been increasing worldwide for reasons that are not exactly clear. 2. Current treatment is largely symptomatic. Because the initial observation that simple plasmid DNA injections resulted in in vivo protein expression and induction of adaptive immune responses to the encoded antigen, the potential of modifying the allergic immune responses by DNA vaccination so as to treat and prevent these diseases has been explored extensively. 3. In the present paper we review preclinical studies using animal models of allergic diseases, with an emphasis on DNA vaccine design, for house dust mite allergens-related allergic asthma.
- 12 May 2006
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 33 (5-6) , 546-550
DNA VACCINES AND ALLERGIC DISEASES
1. Allergic diseases are characterized by inappropriate immune responses to common environmental antigens. The prevalence of these diseases has been increasing worldwide for reasons that are not exactly clear. 2. Current treatment is largely symptomatic. Because the initial observation that simple plasmid DNA injections resulted in in vivo protein expression and induction of adaptive immune responses to the encoded antigen, the potential of modifying the allergic immune responses by DNA vaccination so as to treat and prevent these diseases has been explored extensively. 3. In the present paper we review preclinical studies using animal models of allergic diseases, with an emphasis on DNA vaccine design, for house dust mite allergens-related allergic asthma.
- 24 February 2006
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 36 (3) , 369-376
Characterization of glutathione S‐transferase from dust mite, Der p 8 and its immunoglobulin E cross‐reactivity with cockroach glutathione S‐transferase
Summary: Background Sensitization to mite and cockroach allergens is common, and diagnosis and therapy of allergy can be further complicated by the presence of allergen isoforms and panallergens. Purified recombinant and native allergens are useful for studies to resolve such problems.Objective To assess the allergenicity of native and recombinant mite glutathione S‐transferase (GST) (Der p 8) and study the IgE cross‐reactivity between Der p 8 and cockroach GST.Methods Der p 8 cDNA encoding a new isoform was isolated and expressed in yeast. Native Der p 8 was affinity purified from mite extract. IgE reactivity to native and recombinant Der p 8 was assessed by ELISA using sera from allergic subjects from Taiwan, Singapore and Malaysia. IgE cross‐reactivity between Der p 8 and cockroach GST was examined by IgE inhibition assays.Results Our Der p 8 cDNA encoded a basic isoform (pI=8.5) containing six polymorphic residues located at positions 46, 106, 149, 160, 167 and 184. At least 8 isoforms of native Der p 8 were detected by two‐dimensionalgel and immunoblot analyses. Sera from Taiwanese asthmatics showed 96% and 84% IgE reactivity to native Der p 8 and recombinant Der p 8, respectively. Native Der p 8 showed 75% and 65% IgE reactivity with sera from Malaysia and Singapore, respectively.Conclusions A high frequency of sensitization to mite GST among allergic subjects was observed but the titres of IgE reactivity were low. The IgE cross‐reactivity between mite and cockroach GST suggests that GST is a panallergen.
- 24 February 2006
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 36 (3) , 369-376
Characterization of glutathione S‐transferase from dust mite, Der p 8 and its immunoglobulin E cross‐reactivity with cockroach glutathione S‐transferase
Summary: Background Sensitization to mite and cockroach allergens is common, and diagnosis and therapy of allergy can be further complicated by the presence of allergen isoforms and panallergens. Purified recombinant and native allergens are useful for studies to resolve such problems.Objective To assess the allergenicity of native and recombinant mite glutathione S‐transferase (GST) (Der p 8) and study the IgE cross‐reactivity between Der p 8 and cockroach GST.Methods Der p 8 cDNA encoding a new isoform was isolated and expressed in yeast. Native Der p 8 was affinity purified from mite extract. IgE reactivity to native and recombinant Der p 8 was assessed by ELISA using sera from allergic subjects from Taiwan, Singapore and Malaysia. IgE cross‐reactivity between Der p 8 and cockroach GST was examined by IgE inhibition assays.Results Our Der p 8 cDNA encoded a basic isoform (pI=8.5) containing six polymorphic residues located at positions 46, 106, 149, 160, 167 and 184. At least 8 isoforms of native Der p 8 were detected by two‐dimensionalgel and immunoblot analyses. Sera from Taiwanese asthmatics showed 96% and 84% IgE reactivity to native Der p 8 and recombinant Der p 8, respectively. Native Der p 8 showed 75% and 65% IgE reactivity with sera from Malaysia and Singapore, respectively.Conclusions A high frequency of sensitization to mite GST among allergic subjects was observed but the titres of IgE reactivity were low. The IgE cross‐reactivity between mite and cockroach GST suggests that GST is a panallergen.
- 12 November 2004
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 34 (11) , 1762-1767
Immunoglobulin E reactivity of native Blo t 5, a major allergen of Blomia tropicalis
Summary: Background Blo t 5 is a major allergen of Blomia tropicalis and its complementary DNA (cDNA) has been expressed in both prokaryotic and eukaryotic expression systems. Although the recombinant Blo t 5 has been well characterized, relatively less is known about its native counterparts and the allergenicity comparison of the native and recombinant Blo t 5 allergens has not been reported.Objective The aims of this study are to characterize the native counterpart of Blo t 5, and compare the allergenicity of native and recombinant Blo t 5 by in vivo and in vitro assays.Methods Native Blo t 5 were purified by immuno‐affinity chromatography and characterized by proteomic means. The allergenicity of the allergen was evaluated by skin prick tests, human IgE ELISA, ELISA inhibition and histamine release assays.Results Native Blo t 5 consists of at least five distinct isoforms, ranging from pI 3 to 5.5. Allergenicity assessment of recombinant and native Blo t 5 based on skin reaction, IgE‐binding capacity and histamine release in allergic individuals indicated that there was a good correlation between both forms of Blo t 5 in general. However, data from IgE ELISA inhibition assay revealed the presence of additional unique IgE epitopes in native Blo t 5.Conclusions At least five distinct isoforms of Blo t 5 have been identified. Comparative assessment of native and recombinant Blo t 5 revealed that the allergenicity of these two forms was similar but not completely identical suggesting that the various isoforms of native Blo t 5 may exhibit additional unique IgE epitopes.
- 12 November 2004
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 34 (11) , 1762-1767
Immunoglobulin E reactivity of native Blo t 5, a major allergen of Blomia tropicalis
Summary: Background Blo t 5 is a major allergen of Blomia tropicalis and its complementary DNA (cDNA) has been expressed in both prokaryotic and eukaryotic expression systems. Although the recombinant Blo t 5 has been well characterized, relatively less is known about its native counterparts and the allergenicity comparison of the native and recombinant Blo t 5 allergens has not been reported.Objective The aims of this study are to characterize the native counterpart of Blo t 5, and compare the allergenicity of native and recombinant Blo t 5 by in vivo and in vitro assays.Methods Native Blo t 5 were purified by immuno‐affinity chromatography and characterized by proteomic means. The allergenicity of the allergen was evaluated by skin prick tests, human IgE ELISA, ELISA inhibition and histamine release assays.Results Native Blo t 5 consists of at least five distinct isoforms, ranging from pI 3 to 5.5. Allergenicity assessment of recombinant and native Blo t 5 based on skin reaction, IgE‐binding capacity and histamine release in allergic individuals indicated that there was a good correlation between both forms of Blo t 5 in general. However, data from IgE ELISA inhibition assay revealed the presence of additional unique IgE epitopes in native Blo t 5.Conclusions At least five distinct isoforms of Blo t 5 have been identified. Comparative assessment of native and recombinant Blo t 5 revealed that the allergenicity of these two forms was similar but not completely identical suggesting that the various isoforms of native Blo t 5 may exhibit additional unique IgE epitopes.
- 16 April 2004
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 316 (4) , 991-996
High-level expression of a codon optimized recombinant dust mite allergen, Blo t 5, in Chinese hamster ovary cells
- 16 April 2004
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 316 (4) , 991-996
High-level expression of a codon optimized recombinant dust mite allergen, Blo t 5, in Chinese hamster ovary cells
- 9 April 2004
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 34 (4) , 604-610
Production of monoclonal antibodies for immunoaffinity purification and quantitation of Blo t 1 allergen in mite and dust extracts
Summary: Background Blo t 1 is a cysteine protease‐like allergen from Blomia tropicalis. Recombinant Blo t 1 binds up to 90% of IgE from allergic patients and shows limited cross‐reactivity to Der p 1. The generation of monoclonal antibodies (mAbs) against Blo t 1 is important for the detection, isolation and characterization of the native form of the allergen.Methods Mice were immunized intramuscularly with naked plasmid DNA encoding Blo t 1 gene with in vivo electroporation and boosted intraperitoneally with recombinant Blo t 1. mAbs against Blo t 1 were generated using a methylcellulose‐based hybridoma cloning kit. The native Blo t 1 was isolated by mAb affinity purification and its allergenicity was determined by ELISA. A two‐site ELISA for Blo t 1 was developed using the mAbs generated.Results A DNA‐based immunization protocol induced high titre Blo t 1‐specific antibodies in mice. Six stable hybridoma clones secreting mAbs recognizing the native and recombinant Blo t 1 were generated. The native Blo t 1 was affinity‐purified from a B. tropicalis extract and its allergenicity was determined at 63% using a panel of Singaporean and Malaysian mite allergic patients' sera. A two‐site ELISA was developed, which showed a detection limit of 10 ng/mL of Blot t 1.Conclusion Six Blo t 1 mAbs were successfully generated by DNA immunization. These mAbs are useful for nBlo t 1 immunoaffinity isolation and quantitative immunoassays for Blo t 1 in mite and environmental dust extracts.
- 9 April 2004
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 34 (4) , 604-610
Production of monoclonal antibodies for immunoaffinity purification and quantitation of Blo t 1 allergen in mite and dust extracts
Summary: Background Blo t 1 is a cysteine protease‐like allergen from Blomia tropicalis. Recombinant Blo t 1 binds up to 90% of IgE from allergic patients and shows limited cross‐reactivity to Der p 1. The generation of monoclonal antibodies (mAbs) against Blo t 1 is important for the detection, isolation and characterization of the native form of the allergen.Methods Mice were immunized intramuscularly with naked plasmid DNA encoding Blo t 1 gene with in vivo electroporation and boosted intraperitoneally with recombinant Blo t 1. mAbs against Blo t 1 were generated using a methylcellulose‐based hybridoma cloning kit. The native Blo t 1 was isolated by mAb affinity purification and its allergenicity was determined by ELISA. A two‐site ELISA for Blo t 1 was developed using the mAbs generated.Results A DNA‐based immunization protocol induced high titre Blo t 1‐specific antibodies in mice. Six stable hybridoma clones secreting mAbs recognizing the native and recombinant Blo t 1 were generated. The native Blo t 1 was affinity‐purified from a B. tropicalis extract and its allergenicity was determined at 63% using a panel of Singaporean and Malaysian mite allergic patients' sera. A two‐site ELISA was developed, which showed a detection limit of 10 ng/mL of Blot t 1.Conclusion Six Blo t 1 mAbs were successfully generated by DNA immunization. These mAbs are useful for nBlo t 1 immunoaffinity isolation and quantitative immunoassays for Blo t 1 in mite and environmental dust extracts.